Oregon Opioid Settlement Funds
Since July 2021, the State of Oregon has reached agreement on national lawsuits against several companies for their role in the opioid crisis. Through these agreements, over $600 million will be awarded to Oregon over the course of 18 years.
As of February 2024, funds have been received from:
- Distributor Settlement payments (settlements between the State of Oregon and participating subdivisions and McKesson, Cardinal and AmerisourceBergen)
- Janssen Settlement payments (settlement between the State of Oregon and participating subdivisions and Johnson & Johnson, Janssen Pharmaceuticals, Incorporated, and Ortho-McNeil-Janssen Pharmaceuticals, Incorporated)
- Mallinckrodt Settlement payments (settlement between the State of Oregon and participating subdivisions and Mallinckrodt Pharmaceuticals)
- Teva & Allergan Settlement payments (settlement between the State of Oregon and participating subdivisions and Teva Pharmaceutical Industries, Ltd. And Allergan Pharmaceuticals)
- CVS, Walgreens, and Walmart Settlement payments (settlements between the State of Oregon and participating subdivisions and CVS, Walgreens, and Walmart pharmacies)
- Kroger settlement payments (settlements between the State of Oregon and participating subdivisions and Kroger Co.)
- Publicis Worldwide (not subject to 55/45% split with subdivisions)
- Additional restitution funds from Oregon Department of Justice (not subject to 55/45% split with subdivisions)
Additional payments are pending from settlements with Endo Health Solutions, Hikma Pharmaceuticals, and Purdue Pharma.
These funds can be used for a wide variety of opioid prevention, treatment, and recovery strategies
(Exhibit E Approved Uses).
Settlement funds from opioid manufacturers, distributors, and pharmacies are divided between the State of Oregon (45%) and local jurisdictions (55%) pursuant to
Oregon's intrastate allocation agreements. The state’s share is deposited as it becomes available into the Opioid Settlement, Prevention, Treatment and Recovery (OSPTR) Fund required by
2022 House Bill 4098. This fund is controlled by the 18-member
Oregon Opioid Settlement Prevention, Treatment and Recovery Board. Oregon Health Authority provides staff support to the OSPTR Fund and Board.
Throughout the current fiscal biennium which ends in June 2025, approximately $98.5 million will be deposited into the OSPTR Fund.
In January 2024 the OSPTR Board voted to allocate $27.7 million to the nine
Federally Recognized Tribes in Oregon – this is equivalent to 30% of all funds anticipated this biennium. This 30% set-aside will continue throughout the life of the fund as additional settlement payments are deposited.
After the Tribal set-aside, the OSPTR Board is disbursing the funds across eight categories:
OSPTR Board allocations to date ($114.3 million)
2022 House Bill 4098
2022 House Bill 4098 allows up to 5% of the OSPTR Fund to go to administrative expenses such as staffing, fund management, contracts, and grants management. The administrative budget for the 2024 fiscal year (July 1, 2023-June 30,2024) totaled $1,106,924 or 3% of the state portion of settlement funds received. The administrative budget is collaboratively managed by the OHA Public Health Division and the OHA Behavioral Health Division.